A New Approach in Intensive Care Unit Consciousness Assessment: FIVE Score
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Sep 13, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to assess consciousness in patients who are recovering in the Intensive Care Unit (ICU) after serious brain surgeries or injuries. The main goal is to see how the new FIVE score relates to how long patients stay in the ICU. Researchers also want to understand how this score affects the overall time spent in the hospital, patients' recovery outcomes, and how it compares to other existing scoring systems.
To participate, individuals must be between 18 and 80 years old and have been treated in the Neurosurgical ICU for specific conditions, such as strokes or brain surgeries. However, those over 80, under 18, or with certain medical conditions (like psychiatric illnesses or ongoing substance abuse) won’t be eligible. If you or a family member qualifies, participating in the trial will involve monitoring and evaluation using the FIVE score, which could help improve care for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • between the ages of 18 and 80
- • who were monitored in the Neurosurgical Intensive Care Unit
- • had a history of ischemic or hemorrhagic stroke within the last 6 months
- • underwent infratentorial craniotomy
- • supratentorial craniotomy
- • endoscopic surgery
- • vascular surgery
- • epilepsy surgery
- • hydrocephalus surgery
- • neurovascular intervention
- Exclusion Criteria:
- • patients over 80 years of age
- • under 18 years of age
- • patients who were sedated
- • patients who were administered neuromuscular blockers during intensive care follow-up
- • patients with diagnosed psychiatric illness
- • patients who were alcohol or drug addicts
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Fatih, Turkey
Patients applied
Trial Officials
Ozlem Korkmaz Dilmen, MD
Study Chair
Istanbul University - Cerrahpasa
Yusuf Tunali, MD
Study Director
Istanbul University - Cerrahpasa
Fatma Eren Akcil, MD
Study Director
Istanbul University - Cerrahpasa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported